Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 135460
Corporate User License Price USD 6000
Corporate User License Price INR 406380
Site License Price USD 4000
Site License Price INR 270920
Request a Quote

Report Title

Cedar Pollen Allergy-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Cedar Pollen Allergy-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Cedar Pollen Allergy-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Cedar Pollen Allergy-Pipeline Review, H1 2017



Executive Summary

Cedar Pollen Allergy-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cedar Pollen Allergy-Pipeline Review, H1 2017, provides an overview of the Cedar Pollen Allergy (Immunology) pipeline landscape.

Cedar allergy is a seasonal allergy brought on by an allergic reaction to the pollen from mountain cedar trees. Symptoms include runny nose, itchy and watery eyes, nasal blockage and sneezing. Some suffers also complain of fatigue, mild headache, facial discomfort, sore throat, partial loss of smell and the sensation of ear plugging. Treatment includes antihistamines and decongestants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cedar Pollen Allergy-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cedar Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cedar Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Cedar Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Cedar Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy (Immunology).

The pipeline guide reviews pipeline therapeutics for Cedar Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cedar Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cedar Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cedar Pollen Allergy (Immunology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cedar Pollen Allergy (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cedar Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cedar Pollen Allergy-Overview

Cedar Pollen Allergy-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cedar Pollen Allergy-Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Cedar Pollen Allergy-Companies Involved in Therapeutics Development

ALK-Abello A/S

Astellas Pharma Inc

Japan Tobacco Inc

REGiMMUNE Corp

Stallergenes Greer plc

Cedar Pollen Allergy-Drug Profiles

ASP-4070-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Cedar Pollen Allergy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JCC-LAMP-Vax-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGI-1001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STG-120-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TO-206-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Cedar Pollen Allergy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cedar Pollen Allergy-Dormant Projects

Cedar Pollen Allergy-Discontinued Products

Cedar Pollen Allergy-Product Development Milestones

Featured News & Press Releases

Aug 07, 2015: ALK's partner for Japan reports positive Phase II/III trial results for Japanese Cedar SLIT-tablet

Mar 09, 2015: Immunomic Therapeutics to Present at BIO-Europe Annual Conference

Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting

Apr 24, 2013: Immunomic Therapeutics Announces Interim Data Analysis Of Phase I Study To Treat Japanese Red Cedar Allergy

Nov 08, 2012: Immunomic Therapeutics Doses First Patient In Phase I Clinical Trial Of JRC-LAMP-Vax Vaccine To Treat Japanese Red Cedar Allergy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Cedar Pollen Allergy, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Cedar Pollen Allergy, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Cedar Pollen Allergy-Pipeline by ALK-Abello A/S, H1 2017

Cedar Pollen Allergy-Pipeline by Astellas Pharma Inc, H1 2017

Cedar Pollen Allergy-Pipeline by Japan Tobacco Inc, H1 2017

Cedar Pollen Allergy-Pipeline by REGiMMUNE Corp, H1 2017

Cedar Pollen Allergy-Pipeline by Stallergenes Greer plc, H1 2017

Cedar Pollen Allergy-Dormant Projects, H1 2017

Cedar Pollen Allergy-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

ALK-Abello A/S, Astellas Pharma Inc, Japan Tobacco Inc, REGiMMUNE Corp, Stallergenes Greer plc


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand